Drug Type Monoclonal antibody |
Synonyms IL12 L19L19, IL12-L19-L19, IL12-L19L19 + [1] |
Target |
Action inhibitors, stimulants |
Mechanism EDB-FN inhibitors(Human fibronectin extra domain B inhibitors), IL-12R stimulants(Interleukin-12 receptor stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Phase 2 | Switzerland | 27 Apr 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | Germany | 01 Jul 2020 | |
Advanced Malignant Solid Neoplasm | Phase 1 | Italy | 01 Jul 2020 | |
Advanced Malignant Solid Neoplasm | Phase 1 | Switzerland | 01 Jul 2020 | |
Metastatic Solid Tumor | Phase 1 | Germany | 01 Jul 2020 | |
Metastatic Solid Tumor | Phase 1 | Italy | 01 Jul 2020 | |
Metastatic Solid Tumor | Phase 1 | Switzerland | 01 Jul 2020 | |
Diffuse Large B-Cell Lymphoma | Phase 1 | Italy | 21 Jun 2020 |
Phase 1 | 20 | disrluotqy(zxjbhbbndu) = One patient in cohort 3 (0.5 μg/kg) developed a DLT (G3 transient AST/ALT increase) xctlvihrsa (hzbkjzhdfo ) View more | Positive | 26 Feb 2024 |